Discover toplines results of Cerevel Therapeutics' Phase 3 TEMPO-3 trial for tavapadon in Parkinson's disease treatment. Statistically significant efficacy and safety findings were revealed.
On Thursday the Justice Dept. filed an antitrust suit against Apple. The suit joins two others already filed against Google. How much this will affect the market in the long run is up for grabs.
AbbVie seals deal with Landos Biopharma at $20.42/share, totaling $137.5 million plus CVR. Acquisition targets NX-13, promising oral treatment for ulcerative colitis & Crohn's disease.
Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset Kv7-7000's Phase 3 trial this year, reducing late-stage risks.
UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy.
AbbVie's growth outlook in 2024 as William Blair upgrades, highlighting strong performance in Humira erosion management, strategic acquisitions, and a 3.8% dividend yield.
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
